Clinical |
|
|
Clinic visits |
In-person visits |
Telehealth visits for non-urgent
follow-ups |
Workforce |
In-person work week |
Work from home, staggered work
schedule |
Research |
|
|
Site monitoring |
In-person sponsor visits |
Video-link sponsor
visits |
Prioritization of new diagnostics and therapeutics |
Conventional FDA
review |
Fast track FDA review |
Database |
Separate data collection and storage |
Database
sharing |
Protocol accommodations |
Administration of drug in hospital setting |
Shipping investigational agent to patient’s home |
Government agencies |
Visit to FDA and EMA |
Work from home makes more
flexible schedules, easier access |
Other |
|
|
Rechanneling efforts |
Investigators physically met at institution or
national/international meetings to share data |
Video conferencing
facilitates data sharing and idea generation as well as environmental
impact (reduction in carbon footprint and pollution resulting from loss
of industrial activity and reduced travel) |
Collaborations
|
Competition among research groups
|
Aligning resources and talents across borders and institutions
Accessing and leveraging non-pediatric oncology disease research to
interrogate potential oncolytic efficacy
|